Skip to main content

Dr. Julia E. Mcguinness, M.D.

Medical Oncology (Medical Oncology Physician)

  • Medicare participating

At a glance

Medical school
Baylor College of Medicine (2015)
Years since graduation
11
In the NPI registry since
2015
Medicare patients seen, 2024
80

The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is

Education and training

  • 2015Medical school: Baylor College of Medicine
  • 2015Registered with an NPI (national billing number; not a license date)

Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).

Specialties and state licenses

  • Medical Oncology Physician primary
    NY license 288562
  • Hematology & Oncology Physician
    NY license 288562

As reported to the NPI registry. To confirm a license is current, check the state medical board.

Map: Medical Oncology per capita by county →

Where they work

Hospitals

Medical groups

Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.

Medicare patients and services

Medicare patients, 2024
80
Services billed
453
Patients’ average age
74
Most frequent Medicare services, 2023
ServiceTimesPatients
Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes10524
Established patient office or other outpatient visit, 40-54 minutes10419
Established patient office or other outpatient visit, 30-39 minutes6438
Established patient office or other outpatient visit, 20-29 minutes1613
New patient office or other outpatient visit, 60-74 minutes1414
Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes1111

Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.

Medicare prescriptions

Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.

Payments from drug and device companies

In 2025, 5 companies reported 12 payments worth $4,255 in total to this clinician.

By type
Consulting Fee$2,800
Travel and Lodging$975
Food and Beverage$479

What the payments were for

Largest payments other than meals
DateCompanyWhat it was forAmount
Nov 10, 2025Novartis Pharmaceuticals Corporation
Nov 10, 2025
Consulting Fee
KISQALI · Oncology
$2,800
Oct 6, 2025Novartis Pharmaceuticals Corporation
Oct 6, 2025
Travel and Lodging
KISQALI · Oncology · travel to Fort Lauderdale, FL
$410
Oct 29, 2025Novartis Pharmaceuticals Corporation
Oct 29, 2025
Travel and Lodging
KISQALI · Oncology · travel to Fort Lauderdale, FL
$350
Oct 6, 2025Novartis Pharmaceuticals Corporation
Oct 6, 2025
Travel and Lodging
KESIMPTA · Neurology · travel to Fort Lauderdale, FL · in-kind
$215

Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.

From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.

Who received the most in New York →

Industry-funded research

Named as a principal investigator on 5 industry-funded studies in 2025, from 5 companies. The companies reported $125,146 in research payments for these studies, mostly to the institutions running them.

  • (VELA) Study of BLU-222 in Advanced Solid Tumors
    Sanofi US Services Inc. · Terminated · NCT05252416
  • A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer
    Jazz Pharmaceuticals Inc.
  • The COMPASSHER2 trials comprehensive use of pathologic response assessment to optimize therapy in HER2POSITIVE breast cancer COMPASSHER2 residual disease rd a doubleblinded phase iii randomized trial of TDM1 compared …
    Pfizer Inc.
  • A Phase 1/2 Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of BLU-222 as a Single Agent and in Combination Therapy for Patients with Advanced Solid Tumors
    Blueprint Medicines Corporation
  • A randomized phase 3 double-blinded study comparing the efficacy and s
    GlaxoSmithKline, LLC.

From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.

Other Medical Oncology clinicians in New York

Sources

NPI registry (CMS NPPES, November 2026; record last updated April 19, 2021), Medicare Care Compare, Medicare Physician & Other Practitioners (2024), Medicare Part D Prescribers (2024) and Open Payments (2025). Information is self-reported or billed data and may be out of date; call before visiting.

NPI 1003201435. Official NPI registry record (opens in a new tab). Clinicians can correct their information in NPPES; changes appear here after our next monthly update.